Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces ...

Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to ...

High manufacturing costs limit access to cell and gene therapies and make it harder to bring new products to market, according to VIVEbiotech CEO, Jon Alberdi, who says cheaper production processes ...

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk.